Eurofins Launches the Second Tranche of a Buy-back Programme of Its Own Shares
December 22 2022 - 12:15AM
Business Wire
Regulatory News:
Eurofins (Paris:ERF):
Following the announcement on 3 October 2022 to buy-back some of
its own shares (ISIN FR0014000MR3) (the “Share Repurchase Plan”)
and the completion of the first tranche, Eurofins Scientific SE
(the “Company”) (EUFI.PA) has mandated an independent provider of
financial services to execute the second tranche of this
programme.
The Share Repurchase Plan allows the acquisition of a maximum
amount representing up to 2% of the Company’s share capital, over a
maximum of twelve months as per the authorisation granted by the
Company’s Extraordinary General Meeting of shareholders held on 25
April 2019 (the “EGM”). The Company may at any time interrupt this
programme in view of market conditions and/or evolution of its
investment strategy.
The shares to be purchased under this programme will be
primarily used to hedge the Company’s Long-Term Incentive plans but
may also be cancelled, used to partially finance acquisitions or
for other purposes approved by the Board of Directors and within
the authorization of the EGM.
The first tranche was completed on 3 December 2022. Between 3
October and 3 December, 121,493 shares were repurchased at an
average price of 61.31 EUR, representing 0.06% of the current share
capital. It is currently intended that all purchased shares may be
used as previously communicated, including to cover the Company’s
Long-Term Incentive plans as approved by the Board of Directors at
its meeting on 19 December 2022.
The second tranche will cover a maximum volume of up to one
million shares or 0.52% of the Company’s current share capital. The
purchase period will start on 22 December 2022 and will last until
3 March 2023 at the latest.
Notes to Editors:
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. Eurofins is the global leader in
food, environment, pharmaceutical and cosmetic product testing, and
in discovery pharmacology, forensics, advanced material sciences
and agroscience Contract Research services. Eurofins is also a
market leader in certain testing and laboratory services for
genomics, and in the support of clinical studies, as well as in
BioPharma Contract Development and Manufacturing. The Group also
has a rapidly developing presence in highly specialised and
molecular clinical diagnostic testing and in-vitro diagnostic
products.
With over 61,000 staff across a decentralised and
entrepreneurial network of 940 laboratories in 59 countries,
Eurofins offers a portfolio of over 200,000 analytical methods to
evaluate the safety, identity, composition, authenticity, origin,
traceability and purity of a wide range of products, as well as
providing innovative clinical diagnostic testing services and
in-vitro diagnostic products.
The Group’s objective is to provide its customers with
high-quality services, innovative solutions and accurate results on
time. Eurofins is ideally positioned to support its clients’
increasingly stringent quality and safety standards and the
increasing demands of regulatory authorities as well as the
requirements of healthcare practitioners around the world.
In 2020 and 2021, Eurofins reacted quickly to meet the global
challenge of COVID-19, by creating the capacity to help over 20
million patients monthly who may have been impacted by the pandemic
with our testing products and our services and directly supporting
healthcare professionals working on the front line to fight the
virus. The Group has established widespread PCR testing
capabilities and has carried out over 40 million tests in its own
laboratories, is supporting the development of a number of vaccines
and has established its SAFER@WORK™ testing, monitoring and
consulting programmes to help ensure safer environments, travel and
events during COVID-19.
Eurofins has grown very strongly since its inception and its
strategy is to continue expanding its technology portfolio and its
geographic reach. Through R&D and acquisitions, the Group draws
on the latest developments in the field of biotechnology and
analytical chemistry to offer its clients unique analytical
solutions.
Shares in Eurofins Scientific are listed on the Euronext Paris
Stock Exchange (ISIN FR0014000MR3, Reuters EUFI.PA, Bloomberg ERF
FP).
Until it has been lawfully made public widely by Eurofins
through approved distribution channels, this document contains
inside information for the purpose of Regulation (EU) 596/2014 of
the European Parliament and of the Council of 16 April 2014 on
market abuse, as amended.
Important disclaimer:
This press release contains forward-looking statements and
estimates that involve risks and uncertainties. The forward-looking
statements and estimates contained herein represent the judgment of
Eurofins Scientific’s management as of the date of this release.
These forward-looking statements are not guarantees for future
performance, and the forward-looking events discussed in this
release may not occur. Eurofins Scientific disclaims any intent or
obligation to update any of these forward-looking statements and
estimates. All statements and estimates are made based on the
information available to the Company’s management as of the date of
publication, but no guarantees can be made as to their completeness
or validity.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221221005471/en/
For more information, please visit www.eurofins.com or
contact: Investor Relations Eurofins Scientific SE Phone: +32 2
766 1620 E-mail: ir@eurofins.com
Enerplus (NYSE:ERF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Enerplus (NYSE:ERF)
Historical Stock Chart
From Jul 2023 to Jul 2024